Making People Smile For Generations To Come

Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs.

We bring humility, creativity and a relentless passion to achieve our purpose: to make people smile.

Rare Metabolic Diseases

Bone and Mineral

Haemato-Oncology

Intractable Haematological Diseases and Haemato-Oncology

Rare Diseases

Rare Diseases

Office Locations in Europe & Middle East

Choose country: (*coming soon)

MIDDLE EAST

البحرين (Bahrain)
الكويت (Kuwait)
سلطنة عُمان (Oman)
قطر (Qatar)
المملكة العربية السعودية (Saudi Arabia)
الإمارات العربية المتحدة (UAE)

Global Employees

Group Companies

Drugs in Development

Year Heritage

Our Philosophy

The Kyowa Kirin Group companies strive to contribute to the health and wellbeing of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

Core Values

Our goal is clear: to do everything we can to answer the
unmet medical needs of patients, their families and
medical professionals, and to do it as quickly as possible.
Because every moment counts.

Dubai:
Kyowa Kirin Pharma FZ-LLC
Office 106, Building 49, Dubai Healthcare City,
Dubai, United Arab Emirates.
PO Box 62468

T: +971 4 581 3700

Riyadh:
Kyowa Kirin Offices
Floor 2, Building 7
Salehiya Trading Company
Abdullah Sulaiman Al Hamdan Street, Sulaimaniya District
Riyadh 11421
Kingdom of Saudi Arabia

Copyright © Kyowa Kirin International plc. All rights reserved. This website is developed and funded by Kyowa Kirin International plc.

Kyowa Kirin International plc is a company registered in Scotland (company number SC198780) with registered address at Galabank Business Park, Galashiels TD1 1QH, United Kingdom.

KKI/GCC/KKI/0067 – June 2025

Skip to content